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ABSTRACT
Background: Sunitinib is a protein tyrosine kinase (PTK) inhibitor that has 
immune-modulating properties. In this context, peripheral blood mononuclear cells 
(PBMC), mainly constituted by lymphocytes, could be a perfect surrogate tissue for 
identifying and assaying pharmacodynamic biomarkers of sunitinib. In this study, we 
investigated the changes in lymphocytes count as pharmacodynamic biomarker in 
metastatic renal cell carcinoma (mRCC) patients under sunitinib therapy. Thereafter, 
we studied the ex vivo effect of sunitinib and SU12262 (active metabolite) on PBMC 
from naïve mRCC patients using a high throughput kinomic profiling method.
Methods: The prognostic value of total lymphocytes count between Day 0 and 
Day 21 (expressed as a ratio D21/D0) was retrospectively investigated in 88 mRCC 
patients under sunitinib therapy. PTK PamChip® microarrays were used to explore 
prospectively the ex vivo effect of sunitinib and SU12662 on PTK activity in PBMC 
from 21 naïve mRCC patients.
Results: In this retrospective study, D21/D0 lymphocytes ratio (Hazard Ratio, 
1.83; CI95%, 1.24-2.71; p=0.0023) was independently associated with PFS. 
Interestingly, kinomic analysis showed that D21/D0 lymphocytes ratio and Heng 
prognostic model was statistically associated with the ex vivo sunitinib and SU12662 
effect in PBMC. 
Conclusion: The present study highlights that D21/D0 total lymphocytes ratio 
could be a promising pharmacodynamic biomarker in mRCC patients treated with 
sunitinib. Additionally, it paves the way to investigate the kinomic profile in PBMC 
as a prognostic factor in a larger cohort of mRCC patients under sunitinib therapy.
INTRODUCTION
Renal cell carcinoma (RCC) is the third most 
common malignancy of the urinary tract and is responsible 
each year for 338,000 new cases worldwide [1]. This 
cancer is considered to be an immunogenic tumor 
and a number of immunotherapeutic approaches have 
been exploited so far [2]. Until 2006, cytokines based 
immunotherapy (interferon-α and interleukin-2) was 
the only proven systemic therapy with a limited clinical 
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efficacy. A better understanding of RCC biology has led to 
the approval of new targeted therapies, including kinase 
inhibitors such as vascular endothelial growth factor 
receptor (VEGF-R) and mammalian target of rapamycin 
(mTOR) inhibitors.
The use of kinase array technology to evaluate 
global kinase activities implied in cell signaling (« kinome 
») in tumors from patients and to seek biomarkers for 
kinase inhibitors [3-7] is currently spreading. Recently, 
Anderson et al. have showed that the kinase profiling 
of clear cell RCC tumors could provide a functional 
classification strategy before starting a kinase inhibitor 
therapy [8]. Although these results are very promising, 
this strategy to process biopsy tumor before treatment 
initiation may fail to reflect current tumor dynamics 
and drug sensitivity, which may change during therapy. 
Additionally, processing repeated tumor biopsy cannot 
routinely be performed over the treatment course 
because of the invasive characteristic of the technique. 
Circulating cells could be an ideal biological matrix for 
biomarker discovery. In this context, we hypothesized 
that peripheral blood mononuclear cells (PBMC) could 
be a perfect surrogate tissue for identifying and assaying 
pharmacodynamic biomarkers of kinase inhibitors, as this 
tissue is readily accessible for repeat sampling throughout 
therapy. To the best of our knowledge, no data is currently 
available about the use of PBMC as surrogate tissue for 
the evaluation of global kinase activity in cancer patients.
Sunitinib, the first tyrosine kinase inhibitor 
developed for the VEGF pathway, is currently the standard 
first-line treatment for metastatic RCC (mRCC). Sunitinib 
is known to have immunomodulating properties in 
addition to its antiangiogenic activity [2, 9]. Interestingly 
a study by Powles et al. reported a significant reduction 
in the number of peripheral total lymphocytes (17%), 
CD3 (21%), CD4 (27%) and CD8 (29%) T-cells after 
completion of the first 6-week cycle of therapy in 43 
mRCC patients [10]. No relationship was however found 
between this decline in lymphocytes count and progression 
free survival (PFS). Since each cycle consisted of 4 weeks 
of sunitinib followed by 2 weeks off the drug, it is possible 
that the effects on cell counts may be more marked 
before temporary discontinuation of sunitinib rather than 
at the end of the 6-week cycle. Furthermore, Adotevi 
et al. showed that the overall survival is significantly 
longer in mRCC patients showing a decrease in the 
number of Foxp3+ regulatory T-cells after 2 or 3 cycles 
of treatment [11]. In this context, further investigations 
are required to assess the changes in lymphocytes count 
as pharmacodynamic biomarker. Given PBMC are 
mainly constituted by lymphocytes (~85%) [12], those 
investigations are a mandatory step before the evaluation 
of PBMC as surrogate tissue for kinomic analysis.
The present study aimed first, to retrospectively 
evaluate the changes in lymphocytes count at day 21 after 
sunitinib start in mRCC patients as a pharmacodynamic 
biomarker, and secondly, to assess the global protein 
tyrosine kinase (PTK) activity in PBMC from naïve 
mRCC patients before sunitinib treatment. A high 
throughput kinomic profiling method was employed to 
examine the effects of sunitinib and its active metabolite 
SU12662 on intracellular signaling pathways in PBMC.
RESULTS
Retrospective preliminary study
Eighty-eight mRCC patients treated with sunitinib 
were included. Baseline patients’ characteristics are 
summarized in Table 1. Median age was 62 years old 
[54-68]. The most frequent histological tumor type was 
clear cell carcinoma (71%). According to the Heng 
prognostic index model, most of the patients had an 
intermediate prognosis (57%) and about a third (36%) had 
a poor prognosis. Twenty-three patients (26%) developed 
lymphopenia during the first cycle of sunitinib treatment, 
with seven (8%) of grade ≥ 2.
The median PFS in the cohort was 234 days 
(confidence interval, CI95%, 179-289). In univariate 
analysis (Table 2), the lymphocytes ratio between day 
0 (before treatment starts, D0) and day 21 of treatment 
(D21), was the single hematological ratio at day 21 
associated with PFS. An increase in lymphocyte count 
on day 21 was significantly associated with a poorer 
prognosis (p = 0.0028). Multivariate Cox proportional 
hazards model analysis showed that lymphocyte D21/
D0 ratio (hazard Ratio [HR], 1.83; CI95%, 1.24-2.71; p= 
0.0023), ECOG (Eastern Cooperative Oncology Group) 
performance status 0-1 (HR, 0.44; CI95%, 0.23-0.84; p 
= 0.0135) and body mass index (HR, 0.86; CI95%, 0.80-
0.93; p = 0.0001) were independently associated with PFS.
Basal PTK activity in PBMC from mRCC 
patients and healthy volunteers
In continuum of the previous clinical results, we 
conducted a study to compare the PTK activities in PBMC 
from mRCC patients and healthy volunteers using peptide 
microarrays. The clinical and biological characteristics of 
naïve mRCC patients population (n = 21) before sunitinib 
treatment initiation are summarized in Table 3. Median 
age was 50 [48-57] years in healthy volunteers (n = 12), 
and half of them were male.
A large interindividual variability in kinomic profiles 
(Figure 1A) was observed, especially in mRCC patients, 
which could not be correlated with various baseline clinical 
and biological parameters tested. Even so, unsupervised 
Principal Component Analysis (PCA) showed a tendency 
of separation between patients and healthy volunteers 
(Figure 1B) with a tendency of clustering in the case of 
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Table 1: Baseline characteristics of the retrospective cohort
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Table 2: Results of univariate and multivariate analysis of progression free survival prognostic factors (n=88)
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healthy volunteers. Furthermore, several peptides showed 
significantly lower phosphorylation levels in PBMC from 
patients when compared to healthy volunteers (76 with 
p < 0.05, 45 with p < 0.01) (Figure 1C), suggesting that 
overall kinomic profiles of naïve mRCC patients’ PBMC 
could be differentiated from those of healthy individuals. 
Functional ontology enrichment analysis using Metacore 
software (GeneGO)TM showed that several pathways were 
deregulated in patient PBMC, including immune response 
(FC epsilon RI-, CD28-, CCR5-, CD16- signaling), 
the EGFR (ERK inhibition, PI3K/AKT- and MAPK- 
signaling), FGF-family and FGFR-signaling, along with 
chemotaxis (CXCR4- signaling).
Ex vivo PTK inhibitory effects of sunitinib and 
SU12662
The next step was to study the ex vivo effect of 
sunitinib or SU12662 (active metabolite) in PBMC lysates 
from 21 naïve mRCC patients. Inhibition profiles obtained 
after ex vivo exposure to either sunitinib or SU12662 
showed that PTK substrate phosphorylation levels were 
Figure 1: Basal protein tyrosine kinase activity profiles (Log2Signal) in PBMC from healthy volunteers (n = 12) and 
metastatic renal cell carcinoma patients (n = 21). A. The heatmap shows rows (representing 110 peptides of the “QC List”) sorted 
by hierarchical clustering using Euclidean distance metrics and complete linkage. B. The 3D plot shows 3 new variables (PC1-3) obtained 
after applying Principal Component Analysis (PCA), each point representing a sample colored according to PBMC source. C. The volcano 
plot shows the result of T-test: the effect size, i.e. LFC (Log2Signal (Healthy) - Log2Signal (mRCC)), versus significance (-Log10p). Peptides 
with significant p-values ( < 0.05) are marked in red. 
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Table 3: Baseline characteristics of patients included in the kinomic analysis
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reduced. Interestingly, the inhibitory effect of sunitinib 
was stronger than that of SU12662. A two-way analysis 
of variance (ANOVA) (Figure 2A, 2B) allowed the 
identification of peptides that were significantly inhibited 
(106 and 102 peptides for sunitinib and SU12662, 
respectively, p < 0.05). Putative upstream PTK were 
determined by using Kinexus Kinase Predictor. The top 15 
PTK that were inhibited are presented on kinome trees for 
sunitinib (Figure 2C) and SU12662 (Figure 2D). Amongst 
them, were some that are implicated in immune response, 
in particular Zap70, Src, Fyn, Yes1 and DDR1.
Figure 2: Ex vivo inhibition of sunitinib and SU12662 on protein tyrosine kinase activity in PBMC from metastatic 
renal cell carcinoma patients (n = 21). A. and B. : The volcano plots show the result of an ANOVA post-hoc test. The effect size i.e. 
LFC (Log2Signal (SU12662 A. OR Sunitinib B.) - Log2Signal (DMSO)) versus significance (-Log10P). Peptides with significant p-values 
( < 0.05) are marked in red. BioNavigator® interfaced with R was used to generate the graphs. C. and D. : Upstream kinase analysis of the 
same data set using BioNavigator® interfaced with R, were mapped to a phylogenetic tree of the kinome using the Kinome Renderer tool 
[35]. Only the 15 main kinases inhibited by sunitinib or SU12662 are presented. The size of the circles indicates the specificity score of the 
corresponding kinases and the green color relates to the effect size with lower inhibition being darker. Image reproduced courtesy of Cell 
Signaling Technologies Inc. 
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Correlation of ex vivo inhibition profiles and heng 
prognostic score
The ex vivo inhibition profiles of sunitinib and 
SU12662 were statistically correlated with Heng 
prognostic scores. Thus, mRCC patients with poor 
prognosis presented a lower inhibitory effect of either 
sunitinib (Figure 3A) or SU12662 (Supplementary Figure 
1A). A tendency of separation between intermediate and 
poor prognosis groups was observed after applying PCA, 
and phosphorylation inhibition was significantly different 
between these 2 prognosis groups (53 and 23 peptides for 
sunitinib and SU12662, respectively, p < 0. 05) (Figure 
3B and Supplementary Figure 1B). Using GeneGOTM, 
we observed that signaling pathways including VEGF-
, HGF-, FGFR- and EGFR- for sunitinib and PDGFR 
for SU12662 were statistically more inhibited in the 
intermediate prognosis group. Kinases involved in the 
immune response such as, Itk, Tec, Btk, Lyn, Syk and Zap 
70 were the most inhibited by both sunitinib and SU12662 
in the intermediate group.
Figure 3: Correlation of ex vivo sunitinib-related inhibition profiles in PBMC from metastatic renal cell carcinoma 
patients to Heng prognostic scores. A. The heatmap of LFC (Log2Signal (Sunitinib) - Log2Signal (DMSO)) shows columns (n = 
21) sorted by column mean and rows (representing 110 peptides of the “QC List”) sorted by row mean. When Heng prognostic score was 
overlaid on the data, higher inhibition (lower LFC) corresponded to favorable (▲) or intermediate scores except for 3 outliers (*). B. The 
3D plot shows 3 new variables (PC 1-3) obtained after applying Principal Component Analysis (PCA), each point (n = 19) representing a 
sample colored according to Heng prognostic score. Only intermediate and poor prognostic groups were included in this statistical analysis. 
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Relationship between ex vivo inhibition profiles 
and lymphocytes D21/D0 ratio
Based on the prognostic value of D21/D0 
lymphocytes ratio, we investigated the relationship 
between this ratio and the ex vivo kinomic inhibition 
profiles sunitinib and SU12662. Five patients could not 
be assessed on day 21 due to death (n = 1) and early 
discontinuation of treatment related to severe toxicities 
(n = 4). Interestingly, a linear relationship was found 
with both the ex vivo inhibition profiles of sunitinib (20 
peptides with p < 0.05) and SU12662 (18 peptides with p 
< 0.05). Lower D21/D0 lymphocytes ratio was associated 
with higher phosphorylation inhibition of these peptides 
for sunitinib (Figure 4) and SU12662 (Supplementary 
Figure 2). 
DISCUSSION
This retrospective clinical study is the first to 
show that D21/D0 lymphocytes ratio could be used as a 
pharmacodynamic biomarker in mRCC patients under 
sunitinib therapy. The kinomic study that followed shows 
that both sunitinib and SU12662 induce PTK inhibition 
in PBMC. Additionally, their ex vivo effect on PBMC are 
statistically correlated with both Heng prognostic score 
and D21/D0 lymphocytes ratio. Together, these data 
suggest that a stronger ex vivo sunitinib- and SU12662-
induced inhibition in PBMC kinome profile before 
sunitinib start would be associated with a better prognosis 
in mRCC patients.
  The present retrospective clinical study 
highlights that a decrease in lymphocytes count on D21 
was associated with a longer PFS and could therefore be 
an interesting prognostic factor. Pretreatment lymphopenia 
is traditionally considered as a poor prognostic factor 
in naïve RCC patients [13]. The D21/D0 lymphocytes 
ratio is not necessarily associated with pathological 
values and constitutes a dynamic parameter reflecting 
rapid variations in lymphocytes count under sunitinib 
treatment. Moreover, this ratio seems to be a better 
prognostic factor than either pre-treatment lymphopenia 
or neutrophil to lymphocyte ratio (NLR). Different 
clinical studies have reported that lower baseline NLR 
is associated with longer PFS, suggesting baseline NLR 
as an interesting prognostic factor [14-16]. In the present 
study, lower baseline NLR was only associated with 
longer PFS in the univariate analysis, probably because 
all the patients included in our cohort were treated in 
first line with sunitinib and could therefore have a less 
inflammatory disease than other patients included in the 
Figure 4: Relationship between ex vivo sunitinib-related inhibition profiles in PBMC from metastatic renal cell 
carcinoma patients and lymphocytes ratio D21/D0 (n = 16). The heatmap of LFC (Log2Signal (Sunitinib) - Log2Signal (DMSO)) 
shows 20 peptides (Y axis) which present linear correlation between LFC and lymphocytes ratio (X axis). Each column represents one 
patient. The rows show 20 significant (p < 0.05) peptides derived from a one-way ANOVA. When lymphocytes ratio was overlaid on the 
data, higher inhibition (lower LFC) corresponded to lymphocytes count decreased at D21. Graph on the right show the same results for one 
peptide in a dot plot.
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previous studies. Additionally, the baseline NLR ratio 
indicative of the balance between host immunity and 
cancer-related inflammation does not take account of the 
interindividual variability in the pharmacodynamic effect 
of sunitinib, while the total peripheral lymphocytes D21/
D0 ratio does. The decline in lymphocytes count on D21 
seems unlikely due to a cytotoxic drug effect on peripheral 
lymphocytes for two reasons. Firstly, it was associated 
with an increased PFS in our cohort. Secondly, Krusch 
et al. did not report in vitro cytotoxicity of increased 
sunitinib concentrations on PBMC [17]. By contrast, two 
recent studies have documented that sunitinib enhances 
T-lymphocytes recruitment in tumor microenvironment 
[18, 19]. Thus, the sunitinib-related inhibition of VEGF 
signaling results in up-regulation of chemokines CXCL10 
and CXCL11 (chemoattractant for T-cells) in tumor 
vessels [19]. Additionally, sunitinib is known to reduce 
intratumoral content of myeloid-derived suppressor cells 
in human renal cell carcinoma which can also contribute 
to increase T-cells there [20]. Altogether, these recent 
findings suggest that the association between a decrease 
in lymphocytes count on D21 and a longer PFS could be 
related to a change in the compartmental distribution of 
lymphocytes, characterized by a progressive infiltration in 
tumor tissue and therefore, a better anti-tumor immunity. 
Further investigations are however warranted to support 
this hypothesis.
To the best of our knowledge, the present study 
is the first to show that kinomic profiles of PBMC 
from naïve mRCC patients would be different from 
healthy volunteers. Twine et al. have however reported 
disease-associated differences in transcriptome profiles 
of PBMC from RCC patients compared to PBMC of 
healthy volunteers [21]. They observed heterogeneity in 
the expression of these transcripts across RCC patients. 
Interestingly, we found that the activity of most PTK was 
lower in PBMC from naïve mRCC patients than those in 
healthy volunteers. Immune dysfunction has been well 
documented in RCC patients, especially with the tumor 
infiltrating T-cells anergy [22]. T-cells exhaustion is 
known to be related in part to the expression of inhibitory 
molecules such as Programmed Death 1 (PD-1), whose 
level of expression is enhanced by VEGF-A [23, 24]. A 
recent study showed that the plasma level of VEGF-A 
was 3- to 4-fold higher in mRCC patients than in healthy 
volunteers [25]. Besides, another study documented an 
increased PD-1 expression on circulating T-cells, NK cells 
and monocytes from RCC patients [26]. Taken together, 
these results suggest that the lower PTK activity observed 
in our mRCC cohort could be related to an increased 
expression of PD-1 on PBMC. Another explanation 
may be related to the difference in age between mRCC 
patients and healthy volunteers (69 vs 50 years old). 
Indeed, intrinsic “senescence” is known to compromise 
the activation pathways in lymphocytes from the elderly 
[27]. Additionally, an increase in the number of PD-1-
expressing T-lymphocytes has been documented in aged 
mice, which confers to these cells an exhausted phenotype 
[28]. These different factors could also contribute to the 
lower PTK activity in our mRCC cohort.
The present study is the first to provide kinome 
trees of sunitinib and its active metabolite SU12662 
for PTK in PBMC from naïve mRCC patients. As 
expected, our results showed that sunitinib and SU12662 
inhibited many PTK. In literature, well-known targets 
for sunitinib are Flt-1 (VEGFR-1), KDR (VEGFR-2), 
PDFGR, kit, Flt-3 and RET [29]. Even though these 
targets were not the most inhibited in our study, their 
inhibition validates our approach of using PBMC as 
a model system. Discrepancies between our sunitinib 
kinome tree and the documented tree for sunitinib [30] 
could be explained by the latter being built from the in 
vitro data, which represents sunitinib affinity for purified 
kinases. Additionally, it does not take into account the 
PTK expression level in cells. Finally, the present study 
highlights for the first time a stronger inhibitory effect 
of sunitinib than SU12662 on shared targets like Zap70, 
some Src family kinases (Src, Fyn, Yes1) and DDR1, 
which are respectively involved in lymphocytes activation 
[31], lymphocytes development [32] and T-cells migration 
[33]. These results could constitute a first step to decipher 
these mechanisms in more depth.
The large interindividual variability in sensitivity 
towards both sunitinib and SU12662 could contribute to 
the variability in immunomodulatory effects in mRCC 
patients. Among the different baseline parameters tested, 
the Heng prognostic score was the single factor of 
variability identified. Interestingly, sunitinib and SU12662 
exhibited less ex vivo inhibitory effects in PBMC from 
mRCC patients with a poor Heng prognostic score. 
From clinical data, the recent ESMO clinical practice 
guidelines recommend the use of mTOR inhibitor in first-
line treatment of mRCC patients with poor prognosis, 
while sunitinib remains the golden standard in other 
patients [34]. Taken together, these results suggest that 
sunitinib should be less efficient in mRCC patients 
exhibiting a lower ex vivo inhibitory effects of either 
sunitinib or SU12662 in their PBMC. Additionally, the 
retrospective study highlights the prognostic value of 
lymphocytes D21/D0 ratio. Finally, the kinomic analysis 
has identified a positive relationship between the D21/
D0 lymphocytes ratio and the ex vivo level inhibition by 
sunitinib (or SU12662) for some peptides. In this context, 
these preliminary results pave the way to investigate the 
kinomic profile in PBMC as a prognostic factor in a larger 
cohort of mRCC patients under sunitinib therapy. 
In conclusion, the present study highlights that 
D21/D0 total lymphocytes ratio could be a promising 
pharmacodynamic biomarker in mRCC patients treated 
with sunitinib in first line. Additionally, our data suggest 
that the kinomic analysis in PBMC from mRCC patients 
could be a useful tool to identify good candidates for 
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sunitinib treatment. Moreover, this first kinomic analysis 
in PBMC paves the way to seek mechanisms that drive 
tumor cell to immune escape in mRCC patients under 
sunitinib.
MATERIALS AND METHODS
Retrospective preliminary study
A retrospective study was conducted in mRCC 
patients treated with first-line sunitinib therapy from 
June 2006 to January 2015 in the oncology department 
of Cochin Hospital in Paris, France. From medical 
records, baseline clinical and biological parameters were 
collected. Biological parameters included hematological 
specifications (haemoglobin, leukocytes, neutrophils, 
lymphocytes and platelets) before treatment starts (D0) 
and on day 21 (D21) of the first cycle of treatment. Each 
one was expressed as a ratio (D21/D0) to reflect their 
global evolution besides pathological values. Finally, 
steady-state plasma composite (sunitinib + SU12662) 
exposure at D21 was recorded. 
Patient selection for kinomic profiling
From March 2015 to November 2015, a total of 
21 naïve mRCC patients and 12 healthy volunteers were 
included for the kinomic analysis. The latter was in 
compliance with the Declaration of Helsinki and approved 
by the local medical ethical board (N° 316-12). All 
subjects gave their written informed consent to participate 
in the study.
Sample collection and lysis
PBMC from healthy volunteers and patients (at 
D0) were isolated by density-gradient centrifugation in 
Ficoll. Cells (3.5 million) were lysed in 140 µl of the 
mammalian protein extraction (M-PER) reagent (Thermo 
Scientific, Courtaboeuf, France), supplemented with 
1:100 Halt’s phosphatase and protease inhibitors (Thermo 
Scientific) before centrifugation (12000 rpm, 15 min, 
4°C). Aliquots of the supernatant were stored at -80°C. 
Protein quantification was performed using standard 
Bradford protein assay (Thermo Scientific). PBMC were 
used rather than lymphocytes to minimize the influence of 
FACS sorting on PTK activity.
Kinomic profiling assay
PTK activity profiling was performed using 
a PamStation®12 (PamGene International B.V.,’s 
Hertogenbosch, The Netherlands) and PTK PamChip®4 
with 4 identical arrays. On each array, 142 tyrosine-
containing peptides (13 amino acids long), derived from 
known human phosphorylation sites, are immobilized. 
An assay incubation mixture, containing 2 to 4 µg 
of protein (depending on total protein available), 100 
µM ATP and fluorescein isothiocyanate (FITC) labeled 
antiphosphotyrosine antibody (PamGene), was added in 
each array. The mixture was pumped up and down through 
the porous membrane. Peptide phosphorylation was 
monitored during the incubation by taking images with a 
CCD camera in combination with Evolve software v. 1.2 
(PamGene) allowing real-time recording of the reaction 
kinetics. After washing of the arrays, fluorescence was 
detected at different exposure times (20, 50, 100 and 200 
ms). 
Kinomic profiles of healthy volunteers and 
sunitinib-naïve mRCC patients at baseline (D0) were 
studied by spiking in vehicle (0.1% of dimethyl sulfoxide, 
DMSO) into the assay incubation mixture and performing 
the PTK kinomic assay. The ex vivo inhibitory effect of 
sunitinib and SU12662 in mRCC patient lysates was 
studied by spiking in sunitinib (1 µM), SU12662 (1 µM) 
or DMSO (0.1%) into the assay incubation mixture before 
performing the PTK kinomic assay. 
Statistical analysis
For the retrospective clinical study, descriptive 
statistics used median [interquartile interval] for 
quantitative variables and percentages for qualitative 
ones. Ratio D21/D0 for each hematological parameter 
was assessed to explore the pharmacodynamic effect of 
sunitinib on peripheral blood cells. PFS was analyzed in 
the framework of survival analysis. PFS was estimated 
with the Kaplan-Meïer method. Clinical and biological 
predictive factors were first assessed using univariate 
Cox models. Secondly, factors with a p-value lower than 
0.10 were entered into a stepwise Cox model regression. 
The final multivariate Cox model contained the set of 
factors with a p-value lower than 0.05 by the Wald test. 
All computations were performed with the SAS V9.3 
statistical package (SAS institute Inc., Cary, NC, USA).
For kinomic analysis, image analysis and signal 
quantification were performed using the BioNavigator® 
software v. 6.1 (PamGene), whilst data analysis was 
done using the same software but interfaced with R 
(Bioconductor). Peptides that showed kinetics (increase in 
signal intensity in time) were preselected (“QC list”) and 
Log2-transformed (“Log2Signal”). Log fold change (LFC) 
was determined from ex vivo inhibitor data (Log2Signal 
Inhibitor - Log2Signal DMSO). Ex vivo inhibitor effects 
were evaluated for each peptide using ANOVA. Kinexus 
Kinase Predictor was used to determine putative upstream 
PTK, which were mapped to a phylogenetic tree of the 
kinome using the Kinome Renderer tool. Per-peptide 
differences between Heng pronostic groups were evaluated 
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using two-tailed t-tests and unsupervised multivariate 
clustering of samples was evaluated with Principal 
Component Analysis (PCA). For these analyses, data from 
patients with good prognosis (n = 2) were not included 
in the study as they lacked statistical power. A one-way 
ANOVA was used to compare the lymphocytes ratio 
D21/D0 to LFC signal intensity. MetaCore (GeneGo) TM 
(Thomson Reuters, U.S.A) was used for pathway and 
network analysis.
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